An immunodominant Epstein-Barr virus (EBV)-specific cytotoxic T lymphocyte (CTL) epitope, represented by peptide 68, has been mapped to the EBV nuclear antigen, EBNA 3. The epitope is recognized by class I-restricted CTLs through HLA-B8 and is functionally active on type A but not type B lymphoblastoid cell lines (LCLs). Herein we show that peptide 68 is not expressed as a functional CTL epitope by type A LCLs infected with an EBV B95-8 isolate. CTLs from cultures stimulated with autologous type A IARC-BL74 or QIMR-WIL LCLs lysed autologous cells stimulated with phytohaemagglutinin (PHA blasts) and coated with exogenous peptide 68. No peptide 68-specific CTLs were generated in cultures stimulated with autologous type A B95-8 or type B AG876 LCLs. However, the B95-8 LCL coated with peptide 68 was effective in the induction of a peptidespecific CTL response. A peptide 68-specific CTL clone failed to lyse the B95-8 LCL, type B AG876 LCL and PHA blasts, although such targets were lysed when coated with peptide 68.
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Epstein-Barr virus (EBV) shows a strong tropism for B cells and cells transformed by the virus grow in vitro as lymphoblastoid cell lines (LCLs) and express a limited number of viral gene products. These latent proteins include a family of EBV nuclear antigens (EBNA) 1, 2, 3, 4, 6 and leader protein and a latent membrane protein (LMP) (Dambaugh et al., 1984 ). An alternative nomenclature also in current use designates the EBNA family as EBNA 1, 2, 3a, 3b, 3c and EBNA-LP (Petti & Kieff, 1988) . The virus persists for life in all previously infected individuals as a latent infection in B cells and is apparently restrained by a population of EBV-specific memory T cells, specifically reactive against the functionally defined lymphocyte-detected membrane antigen present on virus-transformed B cells (Rickinson et al., 1981) . EBV-specific memory cytotoxic T lymphocytes (CTLs) can be reactivated in vitro by stimulation with an autologous LCL or B cells freshly infected with EBV. Activated memory cells are predominantly CD8 ÷, class 1-restricted CTLs (Misko et al., 1980) . There are two types, A and B, of EBV that show different geographical distributions and DNA sequence divergence within the BamHI YWH and E regions of the genome (Zimber et al., 1986) . However, indications are that both types of virus are widely distributed and that they can coexist in the same individual (Sixbey et al., 1989) . Allelic polymorphism between type A and type B EBV is evident in each of the EBNA proteins (Rowe et al., 1989; Sculley et al., 1989) and this variation in different EBV isolates has been exploited to generate CD4 + and CD8 +, EBV-specific CTL clones that discriminate between autologous B cells transformed by type A or type B virus (Moss et al., 1988) . EBNAencoded CTL epitopes have been mapped to gene regions that are strictly specific for type A isolates (Burrows et al., 1990a) or shared between type A and type B (Burrows et al., 1990b) . Herein, we show that an immunodominant CTL epitope in the EBNA 3 gene region of type A EBV is not expressed as a functional target epitope by type A LCLs infected with an EBV B95-8 isolate.
Peripheral blood mononuclear cells (PBMC) from two EBV seropositive donors, IM (HLA A1, A11 ; B8, Bw51) and LC (HLA AI, -; B8, B18), were used for the establishment of LCLs, cells stimulated with phytohaemagglutinin (PHA blasts) and for the generation of EBV-specific CTLs. EBV isolates were prepared from the type A cell lines IARC-BL74 (designated BL74) (Zimber et al., 1986) , QIMR-WIL (designated WIL) (Pope et al., 1968) and B95-8 (Miller & Lipman, 1973) , and the type B cell line AG876 (Dambaugh et al., 1984) . The EBV B95-8 isolate used in the present study was obtained from a B95-8 marmoset cell line supplied by the American Type Culture Collection, code CRL-1612, batch number F-3157. Establishment of LCLs by transformation of B cells with exogenous type A or type B EBV isolates was performed essentially as described (Moss et al., 1988 (Moss et al., 1988) .
Primary in vitro stimulation by autologous LCLs was performed in multi-well plates by coculturing 2x106 PBMC from donor IM with 10 s washed, gammairradiated (8000 rad) autologous LCL (type A or type B) in a final volume of 2 ml. In certain experiments, autologous type A LCLs were preincubated with peptide (100 gg/ml in 200 gl) for 1 h at 37 °C, gamma-irradiated (8000 rad), washed and used as stimulator cells. CTLs were also generated in PBMC cultures inoculated with the WIL or B95-8 strains of EBV. The growth medium used throughout was RPMI 1640 containing glutamine (300 mg/l), penicillin (100 international units/ml), streptomycin (100 gg/ml) and 10% heat-inactivated foetal calf serum. Effector cells were harvested from LCLstimulated cultures after 7 days and virus-infected cultures after 14 days, and T cells were separated by rosette formation (Moss et al., 1978) . Rosetted T cells were also maintained as polyclonal CTL lines by restimulation with recombinant interleukin-2 (rlL-2) and specific irradiated transformants. T cell clones and PHA blasts were generated as previously described (Misko et al., 1984; Burrows et al., 1990a) .
To identify the epitope(s) recognized by EBV-specific polyclonal CTLs from donor IM, a series of peptides from the EBNA proteins 1, 2, 3, 4 and 6 and LMP were synthesized (20 to 25 amino acids) (Houghten, 1985) using the known sequences of the prototype EBV B95-8 strain (Baer et al., 1984) . A total of 61 peptides were tested: two peptides from EBNA 1, 38 from EBNA 2, seven from EBNA 3, six from EBNA 4, six from EBNA 6 and two from LMP. Peptides selected were primarily those in which the type A and type B sequences had diverged and/or corresponded to the predicted algorithms of DeLisi & Berzofsky (1985) and Rothbard & Taylor (1988) .
Polyclonal CTLs from donor IM and T cell clones from donor LC were tested for cytotoxicity in standard 5 h SlCr-release assays (Misko et al., 1984) . The target panel included the type A and type B autologous LCLs and autologous PHA blasts. In specified experiments, LCLs and PHA blast targets were preincubated with the appropriate peptide (40 gg/ml, 0.5 ml) for 1 h at 37 °C before labelling with S lCr, or by adding the peptide to labelled targets 1 h prior to adding effector cells (200 ~tg/ml, 20 gl/well). Selected peptides were screened as possible CTL epitopes by assaying their ability to act as targets for EBV-specific polyconal CTLs following adsorption onto autologous PHA blasts. CTLs from donor IM were derived from cultures stimulated with autologous LCLs infected with the B95-8 or BL74 type A strains of EBV. . Specific lysis by polyclonal CTLs generated in culture for 7 days from donor IM. CTLs were initially stimulated with the autologous B95-8 type A LCL (a) or the BL74 LCL (b) and tested against autologous PHA blasts coated with peptides from EBNA 1 (two peptides tested), 2 (38 tested), 3 (seven tested), 4 (six tested), 6 (six tested) and LMP (two tested). Effector :target ratio, 10 : 1.
From the panel of 61 peptides screened, only one (peptide 68) resulted in significant lysis of autologous PHA blasts (Fig. 1) . Curiously, peptide 68 was recognized only by CTLs that had been stimulated with the BL74 LCL (Fig. 1 b) but not by those stimulated with the B95-8 LCL (Fig. 1 a) . The sequence of this peptide derived from the EBNA 3 protein (BERF 1/BLRF 3 reading frames) is TETAQAWNAGFLRGRAYGIDLLRTE (residue 329 to 353).
The failure of the B95-8-stimulated CTL to recognize autologous PHA blasts coated with peptide 68 was not simply due to the lack of lytic activity of such effectors, as was shown by the representative patterns of lysis in Fig.  2 . CTLs derived from donor IM after stimulation with B95-8, BL74, WIL or AG876 LCL were equally competent in lysing the corresponding autologous LCL targets in a S lCr-release assay. Since LCLs may present multiple EBV type-specific and type-cross-reactive CTL epitopes, PHA blasts clearly provide a more appropriate target for the study of individual epitopes when assaying polyclonal effectors, as is evident in Fig. 3 . Typical data from one of several experiments show that only polyclonal CTLs which had been initially stimulated with the BL74 or WIL type A LCLs lysed autologous PHA blasts coated with peptide 68; CTL stimulated with the type A B95-8 or type B AG876 LCLs failed to lyse peptide-pulsed PHA blasts (Fig. 3a) . No peptide 68-specific CTL activity was generated in cultures infected with EBV B95-8, whereas cultures infected with the EBV WIL isolate gave a significant peptide-specific CTL response (Fig. 3b) . Representative cytotoxicity data obtained from donor IM (Fig. 4) show that the autologous B95-8 LCLs presented exogenous peptide 68 for T cell recognition and that the peptide acted not only as a target epitope but also as an inductive epitope by specifically reactivating memory T cells in vitro. However, the B95-8 LCL without adsorbed peptide again was completely ineffective in generating a peptide-specific response. In contrast, BL74 LCL, both with and without adsorbed peptide, stimulated a potent peptide 68-specific CTL response.
EBV-specific type A-specific T cell clones (CD8 +, class I-restricted) were established from donor LC in cultures stimulated with autologous BL74 LCLs and screened for their ability to lyse autologous PHA blasts and type B LCLs coated with peptide 68 (data not shown). Clone 27 satisfied these criteria and the cytotoxicity data in Fig. 5 show the typical results obtained with this peptide-specific clone. Clone 27 consistently lysed the autologous B95-8 LCL coated with peptide 68 but not those which lacked exogenous peptide. Moreover, clone 27 lysed allogeneic B95-8 and AG876 LCLs, and PHA blasts from an HLA-B8 compatible donor (IM), providing that the target cells were coated with peptide 68; lysis of the BL74 LCL from donor IM by clone 27 was independent of exogenous peptide effects.
There are at least two possibilities to explain our finding that type A-specific CTLs can distinguish between the B95-8 LCL and other type A LCLs. First, there may be EBV sequence divergence within CTL epitope regions in type A viruses. Since, in the host, EBV-infected B cells are apparently under constant surveillance by CTLs, there is likely to be immune pressure on the virus continually to alter regions that encode CTL epitopes. Such epitopic drift has already been assumed to account for the observed CTL discrimination between type A and type B LCLs (Moss et al., 1988) and has been demonstrated in other viruses where specific CTL recognition of peptide epitopes has been found to be dependent on critical amino acid residues (Bastin et al., 1987; Joly et al., 1989; Takahashi et al., 1989) . By assuming that peptide 68 represents a natural peptide epitope on the B95-8 LCL and differs in sequence from the equivalent peptide on the BL74 and WlL LCLs, it is not surprising that stimulation with the B95-8 LCL failed to generate a peptide 68-specific CTL response in individuals who possessed memory to the wild-type epitope. This subtle CTL discrimination at the level of naturally presented peptides obviously can be disrupted by adding a sufficient amount of exogenous peptide 68 to appropriate target cells to facilitate cl"ossreactive lysis. However, the cross-reactive recognition of exogenous peptide 68 clearly reflects the close structural similarity between peptide 68 and the equivalent peptide on the BL74 and WIL LCLs, because unrelated peptide epitopes from different EBNA proteins do not trigger lysis when added exogenously to the B95-8 LCL (unpublished observations). Second, there may be a selective dysfunction of the epitope's processing or presentation. Endogenous viral proteins are normally processed by proteolytic degradation to yield peptides which bind to the major histocompatibility complex molecules and are subsequently presented at the cell surface to the T cell receptor (Townsend & Bodmer, 1989) . However, synthetic peptides corresponding to contiguous residues of the protein sequence do not always represent the naturally processed peptide fragments, and the failure of peptide 68-specific CTLs to kill the B95-8 LCL may simply reflect the absence from the cell surface of an appropriate peptide fragment following the natural processing of the EBNA 3 protein. Recent evidence from the murine cytomegalovirus system suggests that virus-encoded regulatory gene products selectively interfere with presentation of phosphoprotein pp89 for recognition by class I-restricted CTLs (Del Val et al., 1989) . This immunodominant viral protein is expressed in the immediate early phase of infection and the antigenic expression of the protein obviously does not guarantee its effective presentation to CTLs. Likewise, EBNA 3 is expressed antigenically in the B95-8 LCL refractory to lysis by peptide 68-specific CTLs and viral control mechanisms that selectively inhibit the presentation of peptide 68 to CTLs may operate in EBV. Although EBV-infected Burkitt's lymphoma cells evidently express down-regulated levels of selective class I antigens (Masucci et al., 1987) , it is unlikely that the surface expression of HLA-B8 molecules on the B95-8 LCL has been compromised in view of the efficient capacity of such transformants to present exogenously derived peptide 68.
The life cycle of EBV is important in modulating epitope/CTL selection strategies. Several options are available to EBV following the infection of B cells. The virus may enter a lytic cycle or latently transform its target cell. It has also been argued persuasively that a reservoir of 'silently' infected B cells may persist in the host and evade CTL recognition by expressing low levels of HLA class I antigens and adhesion molecules and by not expressing EBNAs 2 to 6 (Klein, 1989) . Only the virus-transformed B cells express the full family of EBNA proteins thereby providing a potentially rich source of immunogenic targets for CTL surveillance. Presumably any effective selective pressure by EBNAspecific CTLs would have to be exerted on transformed B cells. These cells may arise periodically in the host during episodes of EBV recrudescence or reinfection and their continual elimination by CTLs could provoke CTLdriven epitope variation and the maintenance of a potent memory T cell compartment, a feature of most healthy virus carriers.
